Lucas Silva | Senior Specialist
Aptar Pharma

Lucas Silva is a Molecular and Cellular Biologist by academic training from the University of Lisbon and currently is working as a Senior Specialist leading the Analytical services at Nanopharm, an Aptar Pharma company.
Prior to his experience in Nanopharm, Lucas did a research internship at University College London focused on the development of particle engineered Dry Powder Inhalers (DPIs) for pulmonary infections.
With over 8 years of immersion in the pharmaceutical industry, Lucas has cultivated expertise spanning analytical services, formulation technology, and drug delivery devices, predominantly within the realm of research and development, particularly in orally inhaled and nasal drug products.
His key research areas are the development of more realistic respiratory and nasal analytical methods, the application of specialized in vitro performance data to de-risk and accelerate drug product development.
Lucas has showcased his research findings at numerous international conferences through both poster presentations and podium talks. Additionally, he has contributed as a co-author to a peer-reviewed paper centred on enhancing impactor testing for assessing the bioequivalence of DPIs.
Currently, Lucas actively engages in discussions within the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), contributing valuable insights to navigate the evolving landscape of inhaled and nasal drug products.